cas 17412-23-6|| where to buy 6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

Nom du produit:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

Unité d'emballage	Stock disponible	Prix($)
CM330120-50mg	in stock	ŪŪ
CM330120-100mg	in stock	ǆȤȅ
CM330120-250mg	in stock	ǆƐƚ
CM330120-1g	in stock	ƚȤƴ
CM330120-5g	in stock	Ȗƴƴ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Notes supplémentaires

Verification code*

refresh

: N° CAS:17412-23-6; Formule moléculaire:C8H8ClN3; Point de fusion:-; Code SMILES:CC1=CC(Cl)=NN2C1=NC(C)=C2; Densité:

: Numéro de catalogue:CM330120; Poids moléculaire:181.62; Point d'ébullition:; N° Mdl:MFCD27946129; Stockage:

: Imidazopyridazines; Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.